X4 Pharmaceuticals, Inc 8-K/A

What Happened

• X4 Pharmaceuticals, Inc. (ticker: XFOR) filed a Form 8-K on May 13, 2026 reporting results from its annual meeting. Stockholders approved the Second Amended and Restated 2017 Equity Incentive Plan, increasing shares available under the plan by 1,500,000 shares. The filing also reports the election of three Class III directors and ratification of PricewaterhouseCoopers LLP as the company’s independent auditor, as well as a non-binding “say-on-pay” approval of executive compensation. The full amended plan is filed as Exhibit 10.1 to the 8-K.

Key Details

• Equity plan: Approved increase of 1,500,000 shares to the Second Amended and Restated 2017 Equity Incentive Plan (filed as Exhibit 10.1).
• Director elections (to serve until the 2029 annual meeting):
  • Gary J. Bridger, Ph.D.: For 72,863,269; Withheld 3,510,134; Broker non-votes 6,474,104.
  • Françoise De Craecker: For 73,419,383; Withheld 2,954,020; Broker non-votes 6,474,104.
  • Murray W. Stewart, M.D.: For 71,679,834; Withheld 4,693,569; Broker non-votes 6,474,104.
• Auditor ratification: PricewaterhouseCoopers LLP ratified as independent registered public accounting firm — For 82,734,674; Abstain 43,841; Against 68,992.
• Say-on-pay (non-binding): Executive compensation approved — For 70,932,142; Abstain 20,692; Against 5,420,569. Equity plan vote totals: For 58,679,552; Abstain 9,711; Against 17,684,140; Broker non-votes 6,474,104.

Why It Matters

• The 1.5 million share increase expands the pool available for employee and executive equity awards, which can support recruiting and retention but may lead to future share issuance that dilutes existing shareholders if granted and vested.
• Re-election of the board nominees and ratification of PwC maintain governance continuity. The non-binding approval of executive pay indicates majority shareholder support for compensation practices as disclosed.
• Investors should note the specific vote margins (above) and review the filed amended plan (Exhibit 10.1) and the company’s proxy materials for details on potential dilution, award terms, and governance implications.